Gemcitabine and Carboplatin (Renally Dosed) Regimen for Bladder Cancer

摘要

The GCarbo regimen (Table 1) has been studied in metastatic bladder cancer16 and is recommended as an alternative regimen to first-line chemotherapy in metastatic disease.7 The GCarbo regimen has also been studied as perioperative chemotherapy, specifically neoadjuvant chemotherapy, in locally advanced bladder cancer prior to cystectomy.8'9 Current bladder cancer guidelines, however, recommend against the substitution of carboplatin for cisplatin in the setting of perioperative chemotherapy and suggest consideration of split-dose administration of cisplatin for patients with renal dysfunction, although efficacy of this adjustment remains unproven.